1743 related articles for article (PubMed ID: 16960658)
21. [Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].
Katsaros D; Fracchioli S; Arts HJ; de Vries EG; Danese S; Richiardi G; Arisio R; Gordini G; Van der Zee AG; Suurmeijer AJ; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):463-70. PubMed ID: 10767994
[TBL] [Abstract][Full Text] [Related]
22. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Zhang L; Li Y; Wang Q; Chen Z; Li X; Wu Z; Hu C; Liao D; Zhang W; Chen ZS
Mol Cancer; 2020 Jan; 19(1):10. PubMed ID: 31952518
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard M; van Gastelen MA; de Jong LA; Pluim D; van Waardenburg RC; Ruevekamp-Helmers MC; Floot BG; Schellens JH
Cancer Res; 1999 Sep; 59(18):4559-63. PubMed ID: 10493507
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
25. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein.
Mello FVC; de Moraes GN; Maia RC; Kyeremateng J; Iram SH; Santos-Oliveira R
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290047
[TBL] [Abstract][Full Text] [Related]
27. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.
Volk EL; Rohde K; Rhee M; McGuire JJ; Doyle LA; Ross DD; Schneider E
Cancer Res; 2000 Jul; 60(13):3514-21. PubMed ID: 10910063
[TBL] [Abstract][Full Text] [Related]
28. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
Yang CH; Schneider E; Kuo ML; Volk EL; Rocchi E; Chen YC
Biochem Pharmacol; 2000 Sep; 60(6):831-7. PubMed ID: 10930538
[TBL] [Abstract][Full Text] [Related]
29. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.
Zhang F; Throm SL; Murley LL; Miller LA; Steven Zatechka D; Kiplin Guy R; Kennedy R; Stewart CF
Biochem Pharmacol; 2011 Jul; 82(1):24-34. PubMed ID: 21459080
[TBL] [Abstract][Full Text] [Related]
30. Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.
Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
Adv Exp Med Biol; 1999; 457():161-75. PubMed ID: 10500791
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
Hinoshita E; Uchiumi T; Taguchi K; Kinukawa N; Tsuneyoshi M; Maehara Y; Sugimachi K; Kuwano M
Clin Cancer Res; 2000 Jun; 6(6):2401-7. PubMed ID: 10873092
[TBL] [Abstract][Full Text] [Related]
32. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.
Lee JS; Scala S; Matsumoto Y; Dickstein B; Robey R; Zhan Z; Altenberg G; Bates SE
J Cell Biochem; 1997 Jun; 65(4):513-26. PubMed ID: 9178101
[TBL] [Abstract][Full Text] [Related]
33. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein.
Draper MP; Martell RL; Levy SB
Br J Cancer; 1997; 75(6):810-5. PubMed ID: 9062400
[TBL] [Abstract][Full Text] [Related]
34. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.
Arts HJ; Katsaros D; de Vries EG; Massobrio M; Genta F; Danese S; Arisio R; Scheper RJ; Kool M; Scheffer GL; Willemse PH; van der Zee AG; Suurmeijer AJ
Clin Cancer Res; 1999 Oct; 5(10):2798-805. PubMed ID: 10537344
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines.
Izquierdo MA; Neefjes JJ; Mathari AE; Flens MJ; Scheffer GL; Scheper RJ
Br J Cancer; 1996 Dec; 74(12):1961-7. PubMed ID: 8980397
[TBL] [Abstract][Full Text] [Related]
36. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.
Allen JD; Brinkhuis RF; van Deemter L; Wijnholds J; Schinkel AH
Cancer Res; 2000 Oct; 60(20):5761-6. PubMed ID: 11059771
[TBL] [Abstract][Full Text] [Related]
37. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.
Dantzig AH; Shepard RL; Law KL; Tabas L; Pratt S; Gillespie JS; Binkley SN; Kuhfeld MT; Starling JJ; Wrighton SA
J Pharmacol Exp Ther; 1999 Aug; 290(2):854-62. PubMed ID: 10411602
[TBL] [Abstract][Full Text] [Related]
38. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells.
Payen L; Delugin L; Courtois A; Trinquart Y; Guillouzo A; Fardel O
Br J Pharmacol; 2001 Feb; 132(3):778-84. PubMed ID: 11159731
[TBL] [Abstract][Full Text] [Related]
39. Transport of phosphatidylcholine in MDR3-negative epithelial cell lines via drug-induced MDR1 P-glycoprotein.
Abulrob AG; Gumbleton M
Biochem Biophys Res Commun; 1999 Aug; 262(1):121-6. PubMed ID: 10448079
[TBL] [Abstract][Full Text] [Related]
40. Multidrug resistance-modifying components in human plasma with potential clinical significance.
Mülder HS; Pinedo HM; Timmer AT; Rao BR; Lankelma J
J Exp Ther Oncol; 1996 Jan; 1(1):13-22. PubMed ID: 9414384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
